<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> causes recurrent morbidity in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluated if exenatide twice daily (BID) was noninferior to premixed insulin aspart 70/30 BID (PIA) for glycemic control and associated with less <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In this open-label study, <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated adults with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomized to 26-week treatment with exenatide BID (4 weeks 5 μg, then 10 μg) or PIA </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Exenatide BID (n = 181) was noninferior to PIA (n = 173) for A1C control (least squares [LS] mean change -1.0 vs. -1.14%; difference [95% CI] 0.14 [-0.003 to 0.291]) and associated with a lower risk for <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (8.0 vs. 20.5%, P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>LS mean weight decreased by 4.1 kg and increased by 1.0 kg with PIA (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 39.2 vs. 20.8% of patients reached the composite end point of A1C &lt;7.0%, no <z:mp ids='MP_0005456'>weight gain</z:mp>, and no <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (P &lt; 0.001; post hoc analysis) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: In <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated patients, exenatide BID was noninferior to PIA for glycemic control but superior for <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and weight control </plain></SENT>
</text></document>